Blood thinner options for clot patients already on antiplatelets
Part of Heart & circulation, Lungs & breathing clinical trials.
This Phase 3 trial compares the best “blood thinner” approach for people who have a new clot in the leg (DVT) or lung (PE) and who already take antiplatelet medicines for heart or blood-vessel prevention. It aims to find an antithrombotic plan that lowers clot risk while managing bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and understand the study.
- You have a newly diagnosed symptomatic proximal DVT (in the thigh/knee area or higher) and/or a pulmonary embolism confirmed by tests.
- Your doctor plans full-dose blood thinner treatment for at least 3 months.
- You were already prescribed an antiplatelet for secondary prevention of heart/blood-vessel disease (not just to prevent first-time disease).
- You are not at high risk for bleeding and your blood pressure is not extremely high (over 180/110).
- Your clot has not been treated with a full-dose anticoagulant for more than 5 days before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether taking a blood thinner and an additional clot-prevention medicine (antiplatelet) after iliac vein stenting can improve treatment of certain deep vein clots. It may help prevent the clot from coming back or spreading, but it also increases bleeding risk, so careful eligibility screening is important.
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
This study helps you and your doctor decide together whether to continue blood thinners after a first unexpected blood clot. You join after 3 to 6 months of treatment to discuss your options.
This study tests personalized blood thinner treatments for people with blood clots in their lungs. It looks for patients who are older, have kidney problems, or have cancer, to see if adjusting the treatment helps them more.
This trial is testing whether a newer type of blood thinner (called a NOAC) can be used safely right after a heart attack or related event, in addition to the standard two antiplatelet medicines. It focuses on patients who have higher risk signs, like elevated D-dimer levels or a higher PARIS risk score, to see if this approach is safe and effective at preventing future heart problems.
This study compares a clot-removal device (ClotTriever) plus standard care versus standard blood thinners alone for a deep vein clot in the leg. It aims to see which approach better improves leg symptoms and outcomes.
Hear when a new Venous Thromboembolic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.